Marshall Summar, M.D., CNRDI

Rare Disease Institute Provides Innovative Digital Solutions amidst Pandemic with Support from Travere

Telehealth-first care. That’s the approach that many clinics and health centers adopted for preventative and follow up visits in the wake of the pandemic’s arrival. Online and on-phone visits enable healthcare professionals and their patients to manage conditions without the burden of travel or undo risk of exposure to the coronavirus.
RARE-X logo

Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company’s ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment.

Read the full press release >
RARE-X logo

Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).

Read the full press release >
RARE-X logo

Travere Therapeutics Provides Corporate Update and 2021 Outlook

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2020 to be approximately $51 million. Read the full press release >
RARE-X logo

Travere Therapeutics Virtual R&D Day

On December 9, Travere Therapeutics held a virtual R&D day to review the company’s key pipeline programs. The event featured presentations from external experts and the Travere Therapeutics senior management team. Watch the recorded webcast >
Rarecast logo

Eric Dube, Ph.D., Interviewed on Global Genes’ Rarecast Podcast

Eric Dube, Ph.D., Interviewed on Global Genes' Rarecast Podcast: With a New Identity, Travere Therapeutics Seeks to Find Its True Path Listen to the podcast >
Travere Circle Logo

Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO, November 30, 2020 – SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition that often leads to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in the first quarter of 2021. Read the press release >
Rise for Rare - Black Women's Health Imperative

Travere Therapeutics Supports Rare Disease Diversity Coalition’s “Rise for Rare” Campaign

November 18, 2020 - Today, the Black Women’s Health Imperative (BWHI) announced the launch of a comprehensive multi-channel campaign entitled RISE for Rare (#riseforrare). 
Travere Circle Logo

Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.

SAN DIEGO, November 16, 2020 – Retrophin Inc., (NASDAQ: RTRX) today announced that the company has changed its global corporate name to Travere Therapeutics, Inc. Read the press release >
Travere Circle Logo

Travere Therapeutics: Our Brand Story

We come to work every day to do something extraordinary that can make a difference in the lives of the patients we serve. This is the core of who we are at Travere Therapeutics.